Umoja Biopharma, based on research at Purdue University and Seattle Children’s Research Institute, has picked up a series B co-led by SoftBank Vision Fund 2.

Umoja Biopharma, a US-based in vivo immunotherapy platform developer advancing research from Purdue University and Seattle Children’s Research Institute, has closed a $210m series B round co-led by telecoms group SoftBank.
SoftBank co-led the round through its Vision Fund 2 together with Cormorant Asset Management, while life sciences real estate investment trust Alexandria Real Estate Equities participated through its Alexandria Venture Investments unit.
RTW Investments, Temasek, Apeiron Investment Group’s Presight Capital, Caas Capital, an unnamed investment fund associated…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Thierry Heles

Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.